SPOP and colorectal cancer: Our previous studies found that TMEM160 is associated with poor prognosis in patients with colorectal cancer, as it can inhibit the ubiquitination and degradation of programmed death-ligand 1 (PD-L1) by competing with Speckle-type POZ protein (SPOP) to promote immune evasion and radioresistance [24].